Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Receivables (2021 - 2025)

InMed Pharmaceuticals' Change in Receivables history spans 5 years, with the latest figure at -$159977.0 for Q4 2025.

  • For Q4 2025, Change in Receivables fell 606.46% year-over-year to -$159977.0; the TTM value through Dec 2025 reached -$77178.0, up 30.03%, while the annual FY2025 figure was $114690.0, 24.07% up from the prior year.
  • Change in Receivables reached -$159977.0 in Q4 2025 per INM's latest filing, down from -$122160.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $207019.0 in Q4 2023 to a low of -$165188.0 in Q1 2024.
  • Average Change in Receivables over 5 years is $10230.4, with a median of $10198.0 recorded in 2021.
  • The largest YoY upside for Change in Receivables was 14451.57% in 2022 against a maximum downside of 2592.58% in 2022.
  • A 5-year view of Change in Receivables shows it stood at -$638.0 in 2021, then surged by 14451.57% to $91563.0 in 2022, then soared by 126.09% to $207019.0 in 2023, then crashed by 110.94% to -$22645.0 in 2024, then tumbled by 606.46% to -$159977.0 in 2025.
  • Per Business Quant, the three most recent readings for INM's Change in Receivables are -$159977.0 (Q4 2025), -$122160.0 (Q3 2025), and $99715.0 (Q2 2025).